The state takes effective measures to encourage the research and innovation of children's medication, supports the development of new varieties, dosage forms and specifications of children's medication that meet their physiological characteristics, and gives priority to the examination and approval of children's medication.
Innovative drugs refer to drugs with independent intellectual property rights patents. Compared with generic drugs, innovative drugs emphasize new chemical structures or new therapeutic uses, which has not been reported in previous research literature or patents. With the gradual improvement of intellectual property rights in China, the research of innovative drugs will bring high profits to enterprises.
Development prospect of innovative drugs
1, the rise of medical service outsourcing industry has promoted the development of the industry.
The innovative drug manufacturers in China have long faced difficulties such as insufficient R&D strength, limited marketing ability and high circulation cost, which have limited their long-term development. Pharmaceutical outsourcing institutions (including medical CRO, medical CMO and medical CSO) are helpful to solve the above pain points and promote the benign development of innovative pharmaceutical industry in China.
2. The aging population stimulates the market demand for innovative drugs.
The trend of population aging in China is obvious, and it is accelerating. According to statistics, the aging rate in China is much higher than the global average. From 2000 to 2020, the number of elderly people aged 60 and above in China increased from 654.38+0.26 billion to 264 million, and the proportion of the elderly population in the total population increased from 654.38+0.2% to 654.38+0.7% in the same period. It is estimated that the elderly population will reach 2.2% in 2026.54+0. More and more elderly people mean more and more market space for innovative drugs industry, and the demand for innovative drugs will continue to increase in the future.
3. Policies promote the development of innovative drug market.
2009128 October 20 165438 The State Medical Insurance Bureau and Ministry of Human Resources and Social Security issued the Notice of 20 19 on Inclusion of Negotiated Drugs in Class B, which officially announced the results of negotiating drug access. This negotiation * * * involves 150 drugs, including 1 19 new drugs and 3 1 new drugs. In the future, it is expected that a number of innovative drugs will usher in a sharp decline. In addition, from 2065438 to June 2009, 1, the state issued a pilot program for centralized drug procurement and use. September 20 19, the first batch of national drugs "4+7 quantity procurement" was extended to the whole country. Compared with the lowest purchase price of the same variety in the extended area in 20 18, the average decline of 25 selected drugs was 59%. On February 29th, 20 19, the list of 33 varieties of the second batch of national drugs "centralized procurement" was announced. On June 29, 2020, 33 drugs included in the second round of quantity procurement were opened in Shanghai. "Centralized procurement" will make enterprises that used to rely on terminal markets and channel barriers face challenges, and will also prompt some powerful generic drug enterprises to transform their original research drugs and promote the development of innovative drug markets.
Legal basis:
People's Republic of China (PRC) Drug Administration Law
Article 16 The state supports drug innovation that is guided by clinical value and has definite or special curative effect on human diseases, encourages the development of new drugs with new therapeutic mechanism and multi-target systematic regulation and intervention on serious life-threatening diseases or rare diseases, and promotes the progress of drug technology.